£4.0M
The Bristol startup raised the capital from SCVC, Foresight Venture Capital, and Verve Ventures to scale operations and accelerate sensor deployment.
"Our mission is to harness light to redefine the future of sensing."
Verve Ventures
Venture CapitalVerve Ventures is a network-driven venture capital firm based in Switzerland that invests in science and technology start-ups across Europe. Founded in 2010, the company connects private and institutional investors with early-stage opportunities.
Portfolio
7
companies
AUM
£500K
under management
By category
- BioTech£57.0M
- Quantum Computing£12.5M
- AI/ML£9.2M
- Uncategorised£7.6M
- Semiconductor£6.6M
- Other£9.5M
By location
- Cambridge£57.0M
- London£21.8M
- Bristol£14.2M
- Manchester£6.5M
- Munich£3.0M
Portfolio companies
C
CellVoyant
CellVoyant is a biotechnology company developing artificial intelligence platforms to advance novel stem cell therapies.
F
Fractory
An online metal fabrication platform connecting customers with manufacturing partners.
Nuclera
Nuclera builds desktop bioprinters to accelerate protein expression and research workflows.
ORCA Computing
ORCA Computing develops full-stack photonic quantum computing systems.
Soter Analytics
Soter Analytics builds ergonomic wearables and artificial intelligence technology to improve worker safety and prevent workplace injuries.
Zero Point Motion
Zero Point Motion develops ultra-sensitive motion sensors for GPS-denied environments.
View all 7 companiesShow fewer
Team
Steffen Wagner
Co-founder
Steffen is the co-founder and chief executive of Verve Ventures, alongside holding board positions at Biograil and iAccess Partners. He also serves on the private equity investment advisory committee at Swisscanto Asset Management International.
LinkedInLW
Lukas Weber
Co-founder
Lukas serves as co-founder and chief executive of Verve Ventures, following roles at PwC and Goldman Sachs.
LinkedInRecent investments
-20webclip.png)
£57.0M
The Series C financing was led by Elevage Medical Technologies with backing from Patient Square Capital and other investors.
"This significant investment demonstrates continued confidence in our team, our eProtein Discovery system, and our potential to revolutionize the way proteins are made. This funding will accelerate our mission to provide ready-to-use benchtop protein screening and making tools to empower protein scientists around the world. We are excited to enhance our support for our customers, enabling them to make proteins for drug discovery more efficiently and effectively for many years to come."
£7.6M
Octopus Ventures led the seed financing, with participation from Horizons Ventures, Verve Ventures, and Air Street Capital, to commercialise live cell imaging technology.
"University spin-outs like CellVoyant are at the heart of the UK’s thriving biotech ecosystem. CellVoyant sets a new standard in precision and reliability for predicting and controlling stem cell behaviour, which will make cell therapies more accessible to those who need them. We are thrilled to invest into a company that is transforming how patients can benefit from life-changing treatments."
€3.5M
The pre-seed round was led by Atlantic Labs to support the construction of a prototype recycling facility.
"We need to act now and build a scalable and robust battery recycling process. At tozero, we’re committed to challenging the status quo of the material life-cycle to accelerate decarbonisation. This will allow us to enter the electrification era without worries, continue innovation and increase quality of life without compromising"
£12.5M
The Series A round was led by Octopus Ventures, Oxford Science Enterprises, Quantonation, and Verve Ventures.
"Light has a huge part to play in the future of quantum computing as an effective, scalable resource. Our mission is to put photonic systems in the hands of users today so that we deliver value in the short as well as long term,"
